The Oncology Institute Narrows Losses, Eyes Profitability in 2026

Event summary

  • The Oncology Institute reported a 41.6% revenue increase in Q4 2025, with consolidated revenue reaching $142.0 million.
  • Net loss narrowed to $7.5 million in Q4 2025, compared to $13.2 million in the same period the prior year.
  • The company added 9 new capitated contracts in 2025, expanding its managed lives by 260,000.
  • 2026 guidance projects revenue between $630 million and $650 million, with potential for positive Adjusted EBITDA.
  • Cash and cash equivalents stood at $33.6 million as of December 31, 2025.

The big picture

The Oncology Institute's strategic focus on expanding its capitated care model aligns with broader industry shifts toward value-based healthcare. The company's ability to manage costs and scale its delegated arrangements will be key in achieving profitability. With a growing footprint in key states like California, Florida, and Nevada, TOI is positioning itself as a major player in community oncology.

What we're watching

Capitation Expansion
The pace at which The Oncology Institute can scale its capitated model will determine its path to profitability.
Seasonal Pressures
First-quarter Adjusted EBITDA is expected to be negative due to deductible resets and lagged pharmaceutical reimbursement adjustments.
Operational Execution
Whether the company can sustain its revenue growth and manage costs effectively will be critical in achieving its 2026 financial targets.

Related topics

Oncology